1 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, psoriasis, skin disorderActive, not recruitingPhase 32025-08-12NCT04862286